Fluorocholine PET/CT Scan for Cancer Detection
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method for detecting cancer using a special PET/CT scan with 18F-fluorocholine. The goal is to evaluate how effectively this scan identifies tumors that other methods might miss. Individuals with a known or suspected tumor that appears on this scan may be suitable for the trial. Participants will receive standard care and this special scan to determine if it aids doctors in diagnosing cancer more accurately. As a Phase 3 trial, this research represents the final step before FDA approval, providing participants an opportunity to contribute to a potentially groundbreaking diagnostic advancement.
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. It seems likely that you can continue your regular medications since the study involves only a PET/CT scan.
What prior data suggests that the 18F-fluorocholine PET/CT scan is safe for cancer detection?
Research has shown that 18F-fluorocholine PET/CT scans are safe and well-tolerated for imaging. One study found this scan to be a good and safe alternative to another imaging method used in surgery. It is generally safe for patients and usually doesn't cause unpleasant side effects. As this trial is in a late phase, researchers have thoroughly studied the safety of the 18F-fluorocholine PET/CT, enhancing its reliability. So far, there have been no major reports of serious problems, which is reassuring for prospective participants.12345
Why are researchers excited about this trial?
Researchers are excited about the fluorocholine PET/CT scan because it offers a more precise way to detect cancer compared to traditional imaging methods like standard CT or MRI scans. While most imaging techniques identify tumors based on their size and shape, the fluorocholine PET/CT scan targets metabolic activity, allowing it to detect cancer cells based on their biochemical behavior. This can lead to earlier detection of cancers that might be missed with conventional scans. Additionally, the use of 18F-fluorocholine as a tracer provides clearer and more detailed images, potentially improving diagnosis and treatment planning.
What evidence suggests that 18F-fluorocholine PET/CT is effective for cancer detection?
Research has shown that 18F-fluorocholine PET/CT scans, which participants in this trial will undergo, effectively find cancerous tumors. One study showed that this imaging method correctly identified tumors 94.1% of the time, indicating high sensitivity. It also demonstrated a high positive predictive value (PPV) of 97.9%, meaning that when it detected a tumor, it was very likely cancerous. Another study demonstrated its ability to identify specific types of tumors, with a sensitivity rate of 79%. These findings suggest that 18F-fluorocholine PET/CT is a reliable tool for detecting cancer, providing clear and accurate results.678910
Who Is on the Research Team?
Stephan Probst, MD
Principal Investigator
Jewish General Hospital
Are You a Good Fit for This Trial?
This trial is for adults over 18 with known or suspected tumors that may take up a substance called 18F-fluorocholine, according to medical literature. Participants must be able to lie still for the scan and handle an IV injection. It's not suitable for medically unstable individuals, those too large for the PET/CT equipment, or those with severe claustrophobia.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Administration of 18F-fluorocholine followed by a PET/CT scan
Follow-up
Participants are monitored for diagnostic accuracy and adverse events
What Are the Treatments Tested in This Trial?
Interventions
- 18F-fluorocholine PET/CT
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sir Mortimer B. Davis - Jewish General Hospital
Lead Sponsor